ArticleFrontiers in immunology2026
Post-transplant malignancies in Taiwanese kidney transplant recipients: incidence, temporal trends, and immunosuppressive risk factors in a two-decade single-center cohort.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-transplant malignancies (PTMs) remain major late immune-related complications after kidney transplantation, but long-term Asian data integrating immunologic exposures are limited. Methods: We retrospectively analyzed 1,808 kidney transplant recipients from 2002 to 2022 at Taichung Veterans General Hospital, Taiwan. After exclusions, 1,734 patients were eligible. Outcomes included PTM incidence, spectrum, latency, temporal trends, and survival, with prespecified analyses of longitudinal tacrolimus trough levels and cumulative immunosuppressive burden. Results: PTM incidence was 11.7%. Urothelial (bladder 15.8%, upper tract 14.3%) and liver cancers predominated. One third occurred within 5 years with a median latency of 8.2 years. Bladder cancer declined after 2012 (26.7% Conclusions: PTMs in Taiwan are frequent and immunologically shaped, with a distinct urothelial and hepatic predominance and a post 2012 decline in bladder cancer plausibly linked to evolving immunosuppression, surveillance, and reduced carcinogen exposure. Older age and cumulative immunosuppressive burden were associated with PTM development, whereas higher long-term tacrolimus trough levels independently predicted mortality, underscoring the need for individualized immunosuppressive management and cancer type specific surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.